- Home
- » Tags
- » Oclacitinib
Top View
- WO 2017/180788 Al 19 October 2017 (19.10.2017) P O P C T
- Translating Jaks to Jakinibs Massimo Gadina, Danielle A
- Colon Cancer Stemness As a Reversible Epigenetic State
- 2015 Proceedings Book (Pdf)
- Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib
- Therapy of Immune-Mediated Skin Disease Jeanne Budgin, DVM, DACVD Riverdale Veterinary Dermatology Riverdale, NJ
- Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution
- Toceranib Phosphate (Palladia) for the Treatment of Canine Exocrine Pancreatic Adenocarcinoma Margaret L
- Ruxolitinib Combined with Vorinostat Suppresses Tumor Growth and Alters Metabolic Phenotype in Hematological Diseases
- Annual Report 2013
- Oclacitinib (Maleate) Catalog No: Tcsc7611
- 1518 JAK2 46216796 C28H32N4O3 472.58 1/7 4.499 Myelodysplastic Syndromes, Myelofibrosis
- Updates on Immunomodulators Lara K. Maxwell, DVM, Phd, DACVCP
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
- Kinase Inhibition in Autoimmunity and Inflammation
- Verordnung Über Die Verschreibungspflicht Von Arzneimitteln (Arzneimittelverschreibungsverordnung - AMVV)
- Refinement of in Vitro Methods for Identification of Aldehyde Oxidase Substrates Reveals Metabolites of Kinase Inhibitors
- Oclacitinib (Ok- La-Sit-Ti-Nib) Apoquel® Janus Kinase (JAK) Inhibitor
- Treatment of Canine Atopic Dermatitis: 2015 Updated Guidelines from the International Committee on Allergic Diseases of Animals (ICADA) Thierry Olivry1*, Douglas J
- APOQUEL, INN-Oclacitinib Maleate
- US Technical Monograph
- Rivoceranib in Canine Melanoma and Mammary Gland Tumor
- Drugs Targeting the JAK/STAT Pathway for the Treatment of Immune-Mediated Inflammatory Skin Diseases: Protocol for a Scoping Review
- Product Data
- 800155000 22500Amx01833 B
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- S13054-020-03020-3.Pdf
- Tyrosine Kinase Inhibitor As Clinical Application Feasibility in Canine Intractable Tumor Diseases
- WHO Drug Information Vol
- Met Inhibition Revokes IFNγ-Induction of PD-1 Ligands in MET-Amplified Tumours
- Oclacitinib Maleate Oclacitinib Maleate Is a Novel JAK Inhibitor
- Download Product Insert (PDF)
- Dic.2020-8-5.Pdf
- Download Product Insert (PDF)
- Oclacitinib (APOQUEL) Is a Novel Janus Kinase Inhibitor with Activity
- WHO Drug Information Vol
- Innovations in Veterinary Medicine: Exciting New Drug Therapies for Vexing Skin Diseases
- Download Product Insert (PDF)
- Oclacitinib Maleate | Medchemexpress
- Old Drugs for JAK-STAT Pathway Inhibition in COVID-19 Patients
- APOQUEL- Oclacitinib Maleate Tablet, Coated Zoetis Inc. ---Apoquel
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Position Statement Regarding the Use of APOQUEL® (Oclacitinib Tablet
- Oclacitinib Maleate) APOQUEL 5.4 Mg 5.4 Mg Oclacitinib (As Oclacitinib Maleate) APOQUEL 16 Mg 16 Mg Oclacitinib (As Oclacitinib Maleate)